Endocrine Abstracts

Changes in HbA1c and weight after 1 year on dapaglifozina added to the previous treatment.

SGLT2 inhibitors are becoming a common and useful drug to treat type 2 diabetes.

The inhibition of the sodium-glucose co transporters (SLGT2) inhibits also the glucose reabsorption in the proximale tubule and increases the glucose excreted in the urine.

Therefore hyperglycemia decreases and so does weight as happens with the glycosuria. This is a very convenient side effect since type 2 DM is highly associated with overweight/obesity.

We show the results of HbA1c and weight evolution after starting dapaglifozina added to the previous treatment. We evaluate 46 patients; the medium age was 58±8 years. Males represent the 47%.

Initial medium HbA1c 7.9%±1 and medium weight 90±16 kg. After 3 months medium HbA1c was 7.4%±0.7 and weight 87±16.4 kg. After 6 months the medium HbA1c was 7.26%±0.7 and weight 88.2±17 kg. Twenty of those patients were controlled after 1 year, the medium HbA1c was 7.37%±0.86 and medium weight was 87.6±19 kg (initial parameters for this group were HbA1c 8.1%±1.2 and weight 92.4±20 kg).

Uric acid levels were assessed, basal medium levels were 5.25±1.6 mg/dl after 3 months decreased a medium of 0.32 mg/dl (4.9±1.1 mg/dl) in 24 patients. A decreased of 1 mg/dl after 6 months was verified in 11 patients.

Three female patients suffered urinary infection during the first 3 months, only one of them had to stop the therapy. No other adverse effects were observed.

Conclusions: Dapagliflozina is an useful drug for treating type 2 diabetes.

In addition, most of the patients get a lost of weight.

A decrease in serum uric acid levels was observed.

The most common side effect was non complicated urinary infection in the first 3 months that was solved with antibiotic therapy.